Most Popular News Stories on OBR Daily
(Bloomberg) June 11, 2019 - A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care. The complex biological medicines, called antibody drug conjugates (ADCs), have been in development for decades, and are now generating renewed excitement because of the success of one ADC in late-stage testing, a breast cancer treatment called DS-8201.
(ABC News) May 23, 2019 - Seven dietary factors may increase the risk of cancer for American adults aged 20 and over, according to a new study published in the JNCI Cancer Spectrum medical journal. The study, conducted by researchers at Tuft's Friedman School of Nutrition Science and Policy, found that in 2015 over 80,000 new cancer cases were associated with low whole-grain intake, low dairy intake, high intake of processed meats and red meat, low fruit and vegetable intake, and high intake of sugary beverages.
(Bloomberg) June 13, 2019 - The NIH and the FBI are targeting ethnic Chinese scientists, including U.S. citizens, searching for a cancer cure. Here’s the first account of what happened to Xifeng Wu. The dossier on cancer researcher Xifeng Wu was thick with intrigue, if hardly the stuff of a spy thriller. It contained findings that she’d improperly shared confidential information and accepted a half-dozen advisory roles at medical institutions in China.
(BioPharma Dive) May 22, 2019 - The failure of Incyte's epacadostat last year cooled enthusiasm for cancer immunotherapies designed to build upon the strong foundation laid by the PD-(L)1 inhibitor class, now led by Merck & Co.'s Keytruda. Yet early- and mid-stage work continues on agents that either block the defenses against immune response put up by tumor cells or stimulate the body's immune system to fight cancer. A recent count by the Cancer Research Institute, for example, found more than 1,700 combination studies involving PD-(L)1 blockers.
(New York Times) May 17, 2019 - A common dietary supplement may help overcome mutations in the Pten gene. Should patients take it? When Kelley Oliver Douglass got breast cancer, a genetic counselor posed an odd question: Do you and your children have trouble finding hats that fit?
(WBUR/Commonhealth) May 17, 2019 - The Dana-Farber Cancer Institute on Friday scored a major victory in Boston federal court: a ruling that one of its researchers should be listed as an inventor on six patents believed to be worth billions of dollars. The patents are connected to immunotherapy drugs, a powerful new type of cancer treatment that unleashes a patient's own immune system against cancer.
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men in the trial had advanced, heavily pre-treated prostate cancer, olaparib delayed progression of the disease in these patients for a median of 8.3 months, with 35 per cent free of progression for more than a year.
(Bloomberg) May 22, 2019 - The second day into Jose Baselga’s tenure as head of AstraZeneca Plc’s cancer research, his new boss called him in to discuss a rival company’s drug. Under development by Daiichi Sankyo Co., it represented the latest generation of treatments the researcher had tested earlier in his career. The drug could transform the way doctors look at one of the most common forms of breast cancer, Baselga told Astra Chief Executive Officer Pascal Soriot, who was already thinking about a deal.
(CNN) May 22, 2019 - Your diet may have more impact on your cancer risk than you might think, a new study has found. An estimated 80,110 new cancer cases among adults 20 and older in the United States in 2015 were attributable simply to eating a poor diet, according to the study, published in the JNCI Cancer Spectrum on Wednesday.
(Markets Insider) June 10, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. "Antibody-drug conjugates are an emerging class of targeted immunotherapies for cancer. This type of therapy, unlike traditional chemotherapy, is intended to target specific cells," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.